Figure 1.

**RANDOMIZATION**
Randomized n=302  
Ineligible n=17  
Eligible n=285

**XELIRI-Bevacizumab**
Randomized n=143  
Randomized to A but received B n=3  
Never started treatment n=5  
Lost medical records n=1  
Completed treatment (6 cycles) n=88  
Discontinued treatment n=49  
Death n=5  
Toxicity (non fatal) n=20  
Disease progression n=11  
Moved to another hospital n=3  
Voluntary withdrawal n=7  
Other reason n=3  
Dead n=104  
Progressed n=93  
Lost to follow-up n=2  
Still on follow-up n=37

**FOLFIRI-Bevacizumab**
Randomized n=142  
Randomized to B but received A n=4  
Never started treatment n=6  
Lost medical records n=1  
Completed treatment (12 cycles) n=89  
Discontinued treatment n=46  
Death n=4  
Toxicity (non fatal) n=6  
Doctor’s decision n=1  
Disease progression n=18  
Voluntary withdrawal n=8  
Other reason n=6  
Unknown n=3  
Dead n=94  
Progressed n=109  
Lost to follow-up n=6  
Still on follow-up n=42